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Background: Erythromycin, a hydrophobic antibiotic used to treat infectious diseases, is now 
gaining attention because of its anti-inflammatory effects and ability to inhibit osteoclasts 
formation. The aim of this study was to explore a cyclodextrin-erythromycin (CD-EM) complex 
for sustained treatment of orthopedic inflammation.
Methods and results: Erythromycin was reacted with β-cyclodextrin to form a nonhost-guest 
CD-EM complex using both kneading and stirring approaches. Physiochemical measurement 
data indicated that erythromycin and cyclodextrin formed a packing complex driven by inter-
molecular forces instead of a host-guest structure due to the limited space in the inner cavity of 
β-cyclodextrin. The CD-EM complex improved the stability of erythromycin in aqueous solution 
and had a longer duration of bactericidal activity than free erythromycin. Cytotoxicity and cell 
differentiation were evaluated in both murine MC3T3 preosteoblast cells and RAW 264.7 murine 
macrophage cells. The CD-EM complex was noncytotoxic and showed significant inhibition of 
osteoclast formation but had little effect on osteoblast viability and differentiation.
Conclusion: These attributes are especially important for the delivery of an adequate amount 
of erythromycin to the site of periprosthetic inflammation and reducing local inflammation in 
a sustained manner.
Keywords: erythromycin, cyclodextrin, drug stability, bactericidal activity, osteoclastogenesis
Introduction
Up to 20% of patients with total joint replacement will develop radiographic evidence 
of osteolysis and/or aseptic loosening.1–3 Aseptic loosening most likely results from 
an inflammatory response to billions of wear debris particles shed from the prosthe-
sis during normal use. The interaction of macrophages with wear debris is the likely 
determinant of whether wear debris-induced inflammation will be resolved or progress 
to irreversible osteolysis/aseptic loosening.4 A recent approach to limiting osteolysis/
aseptic loosening has focused on inhibiting periprosthetic inflammation by pharma-
ceutical intervention.5–7
Erythromycin, a 14-member lactone ring macrolide antibiotic, has been used for the 
treatment of infectious diseases for the past 50 years.8 In the last decade, erythromycin 
has attracted a great deal of attention because of its additional anti-inflammatory effects 
at subantimicrobial doses.9,10 An example of erythromycin used as an anti-inflammatory 
drug has been demonstrated recently in Japan, where erythromycin was successful in 
treating diffuse panbronchiolitis.11,12 Our previous studies have indicated that erythro-
mycin is a promising treatment for osteolysis/aseptic loosening. First, erythromycin 
inhibited wear debris-induced osteoclastogenesis by inhibition of NF-κB activity in International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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both a RAW264.7 macrophage cell line and in mouse bone 
marrow progenitor cells.13 Second, erythromycin inhibited 
wear debris-induced inflammatory osteolysis in a murine 
osteolysis model.14 Third, oral erythromycin 600 mg/day 
reduced periprosthetic tissue inflammation in 32 patients 
with aseptic loosening who were candidates for surgical 
revision.15 Although we have demonstrated the efficacy of 
orally administered erythromycin in improving periprosthetic 
tissue inflammation, long-term systemic treatment with 
  erythromycin is not recommended in view of the poten-
tial side effects, such as bacterial resistance, nausea, and 
  vomiting. Therefore, it would be advantageous to restrict 
delivery of erythromycin to the inflammatory periprosthetic 
site. However, delivery to and maintenance of prolonged 
erythromycin release at the site of periprosthetic inflamma-
tion presents a considerable challenge.16 We propose that the 
efficiency of erythromycin delivered to a periprosthetic site 
can be increased by improving the chemical stability and 
water solubility of the drug.17,18
Cyclodextrins are cyclic oligomers of glucose that are 
molecular “carriers” with a hydrophilic exterior and a hydro-
phobic cavity. Cyclodextrins are biocompatible and do not 
elicit an immune response in humans.19 Cyclodextrins can be 
divided into three types, ie, α, β, and γ cyclodextrins, based 
on their number of glucose monomers. Cyclodextrins are 
used to improve drug bioavailability by increasing solubil-
ity and/or dissolution through inclusion of water-insoluble 
drugs (like erythromycin) into their hydrophobic cavities,20,21 
improving drug stability,22–24 increasing the permeability of 
water-insoluble drugs, and reducing drug toxicity by making 
the drug effective at lower doses.
Cyclodextrin-drug complexes can be prepared in several 
ways.25 The most common procedure is to stir a mixture of 
cyclodextrins and drugs dissolved by two immiscible solvents 
vigorously. Another procedure is the so-called kneading 
method, which kneads cyclodextrins with drug components 
using a small amount of solvent. The physical force required 
to achieve the process of complex formation is favored 
energetically. Both methods could be used to prepare various 
kinds of water-insoluble drugs.26
Complex formation between cyclodextrin monomers and 
drug molecules via dynamic noncovalent interactions using 
the host-guest model has been well described.19 This model 
commonly involves using cyclodextrins as host molecules 
and attracting hydrophobic guest molecules, such as aromatic 
molecules, which are incorporated into the hydrophobic 
cavity of cyclodextrin through the formation of a hydrogen 
bond under thermodynamically favorable conditions.25 
However, the roles of cyclodextrin and the drug molecules 
could be reversed during complex formation when the drug 
molecules are too large to be incorporated.27 Cyclodextrins 
act as nonhost molecules when forming complexes with 
cyclotetrachromotropylene28 and calcichrome.29 The forma-
tion of a host-guest complex is dependent on the dimensional 
match between the cyclodextrin cavity and the size of the 
guest molecule.
In this paper, we describe the synthesis and character-
ization of a cyclodextrin-erythromycin (CD-EM) complex 
prepared using both the stirring and kneading methods. The 
physiochemical properties (water solubility, stability, and 
CD-EM interaction) and biological activity (cellular behavior 
and bacterial inhibition) of the complex are described. We 
suggest that a CD-EM complex might potentially be applied 
to a prosthetic surface, with sustained release of erythromycin 
to prevent orthopedic infection and aseptic loosening.
Materials and methods
Materials
Erythromycin, β-cyclodextrin, β-glycerophosphate, and a 
tartrate-resistant acid phosphatase (TRAP) assay kit were 
purchased from Sigma-Aldrich (St Louis, MO). An alkaline 
phosphatase (ALP) assay kit was obtained from BioVision 
(San Francisco, CA). Absolute alcohol (100%) was pur-
chased from Deconlab Inc (King of Prussia, PA). Sodium 
phosphate (Na2CO3) and sodium hydroxide (NaOH) were 
purchased from Fisher Scientific (Fair Lawn, NJ). Deuterium 
oxide (D2O) and methanol D4 were obtained from Cambridge 
Isotope Laboratories Inc (Andover, MA), and an α-modified 
minimum essential medium, a live-dead cytotoxicity kit, and 
Dulbecco’s modified Eagle’s medium were purchased from 
Invitrogen (Camarillo, CA). Ascorbic acid was obtained from 
Sigma-Aldrich. Receptor activator of nuclear factor kappa-B 
ligand (RANKL) was purchased from Research Diagnos-
tics Inc (Flanders, NJ). A lactate dehydrogenase assay kit 
was obtained from Roche Diagnostics GmbH (Mannheim, 
  Germany). All chemicals used were of reagent grade.
Preparation of cD-eM complex
We used both a solvent evaporation method (MV) and a 
kneading method (MVI) to incorporate erythromycin into 
the hydrophobic cavity of β-cyclodextrin.30 For the MV 
method, erythromycin was first dissolved in 100% alcohol 
(0.25 g/mL). Dropwise addition of erythromycin solution 
to the saturated CD-H2O (0.125 g/mL) solution was done 
under constant stirring at 800 rpm until the mixed solution 
was homogenous. Using the MVI method, the CD-EM International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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complex was obtained by manually kneading a mixture 
of saturated cyclodextrin-H2O 0.125 g/mL solution and 
erythromycin-alcohol 0.25 g/mL at a molar ratio of 1:1 in a 
ceramic mortar for 3 hours. The complexes obtained by the 
MV and MVI methods were initially frozen at −20°C over-
night and   lyophilized at −30°C and 1.3 × 103 Pa overnight. 
Noninteracted erythromycin mixed with the complex was 
removed by rinsing twice with 100% alcohol. The CD-EM 
was collected by alcohol wash through a 0.8 µm membrane 
filter (Millipore, Bedford, MA). Finally, the CD-EM complex 
was sterilized by exposure to ultraviolet light overnight. The 
sterilized CD-EM mixture was resuspended in sterile distilled 
water (5 mg/mL) just before testing.
Measurement of erythromycin  
concentration
Briefly, 100 µL of the sample solution was mixed with 
100 µL of alkaline solution (0.12 M/L, sodium   phosphate; 
0.25 M/L, sodium hydroxide) and incubated in a 60°C 
water bath for 15 minutes in order to cleave the macrocyclic 
lactone ring of erythromycin.31 After cooling to room 
  temperature, the   samples were read using an ultraviolet-  visible 
  spectrophotometer (BioTek Synergy HT,   Winooski, VT) at 
OD 235 nm. To calculate the erythromycin   concentration, 
a standard erythromycin concentration curve was included 
in each sample measurement. The ratio of erythromycin and 
cyclodextrin incorporated into the CD-EM complex was 
reproducibly obtained and found to be about 1:3.3 (w/w) 
according to this quantification method.
1h-NMr and 13c-NMr spectra analysis
1H-nuclear magnetic resonance (NMR) experiments were 
performed on a Varian-500S spectrometer operating at a 
frequency of 500 mHz and 25°C using a 5 mm AutoX-probe. 
One-dimensional 1H-NMR spectra were recorded, with a flip 
angle of 90°, a spectral width of 4000 Hz, and 256 scans of 
16 K points. Cyclodextrin 14 mg/mL and CD-EM 20 mg/mL 
samples were dissolved in D2O, while erythromycin 6 mg/mL 
was first dissolved in methanol D4 and then mixed with D2O. 
13C-NMR experiments were also performed on the same 
instrument at a frequency of 500 mHz and 37°C for 20 hours. 
Cyclodextrin 30 mg/mL and CD-EM 30 mg/mL samples 
were dissolved in D2O at 37°C.
X-ray diffractometry
The crystalline structures and phases of cyclodextrin, 
erythromycin, and CD-EM (MV and MVI) were characterized 
using  an  x-ray  diffractometer  (Rigaku  SmartLab, 
Woodlands, TX). CuKα radiation (λ = 1.5418Å) was used 
to scan the diffraction angles (2θ) between 5° and 80° at a 
speed of 5°/minute. The spectra were compared with standard 
spectra from the JCPDS card via Jade 5 software in order to 
identify the sample phases and crystalline structures.
Ultraviolet spectrometry
Absorbance spectra of cyclodextrin, erythromycin, and 
CD-EM were obtained using an ultraviolet-visible spec-
trophotometer (BioTek Synergy HT). Briefly, 100 µL of 
cyclodextrin, erythromycin, and CD-EM water solution 
(10 mg/mL) were placed in a 96-well ultraviolet plate 
(Fisher Scientific, Pittsburgh, PA) and mounted onto 
the   spectrophotometer. A scanning wavelength range of 
200–300 nm and a step size of 1 nm were set.
Scanning electron microscopy
The morphologies of the cyclodextrin, erythromycin, and 
CD-EM samples were characterized by scanning electron 
microscopy (SEM, Hitachi S-2400, Japan). All samples were 
coated with gold (Gold Sputter, EFFA coater, Redding, CA) 
before SEM analysis. Morphologies were viewed at a 25 kV 
accelerating voltage.
Stability of cD-eM
Erythromycin was firstly dissolved in 100% of alcohol and 
then suspended in 5 mL of distilled water to make a concen-
tration of 0.1 g/mL. CD-EM mixtures were also dissolved in 
5 mL of distilled water to make a concentration of 0.43 g/mL. 
Both samples were incubated in a 37°C water bath for various 
time periods. A fraction of samples (100 µL) was collected at 
different time points (0, 3, 5, 7, 9, 12, 14, 16, 18, and 20 hours). 
These samples were filtered through syringe filters (Minisart, 
Sartorius Stedim North America Inc, Bohemia, NY) with a 
pore size of 0.45 µm. The filtrates (excluding the undissolved 
CD-EM complex) were then used to measure the erythromycin 
concentration. The percentage of measurable erythromycin 
was plotted against the predefined time points.
Antibacterial activity assay
A modified minimum inhibitory concentration assay 
was developed to measure the bactericidal activity of 
erythromycin released from the CD-EM conjugate. First, a 
Mueller-Hinton broth inoculated with Staphylococcus aureus 
at a concentration of 1–2 × 108 colony forming units/mL 
(OD reading at 625 nm around 0.08–0.1) was prepared. The 
bacterial suspension was then mixed with a known concen-
tration of free erythromycin (64 µg/mL), free cyclodextrin International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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(148 µg/mL), and CD-EM (cyclodextrin 212 µg/mL, 
  erythromycin 64 µg/mL) separately and incubated at 37°C 
for approximately 160 hours. Bactericidal activity was evalu-
ated by dynamic measurement of OD reading at different 
time points. Bacterial culture suspension in the absence of 
erythromycin was included as a positive control. In a separate 
experiment, the bactericidal activity of the CD-EM complex 
at different concentrations (0, 53, 106, 159, and 212 µg/mL) 
was evaluated for up to 24 hours in culture.
effect of cD-eM complex  
on osteoblastic ALP activity
Mouse MC3T3-E1 preosteoblasts (American Type Culture 
Collection, CRL-2593) were plated at a density of 1 × 104 
cells/well in a 12-well plate and cultured in α-modified 
minimum essential medium supplemented with 10% fetal 
bovine serum and a 1% (v/v) antibiotic mixture of penicillin 
and streptomycin at 37°C in a humidified incubator with 5% 
CO2 for 24 hours. The MC3T3-E1 cells were then cultured in 
cell differentiation medium (α-modified minimum essential 
medium supplemented with ascorbic acid 50 µg/mL and 
β-glycerophosphate 10 mΜ) for 16 days in the presence 
of erythromycin (1.6 mg/mL and 16 µg/mL), cyclodextrin 
(3.7 mg/mL and 37 µg/mL) and CD-EM (5.3 mg/mL and 
53 µg/mL), respectively. Culture media and drugs were 
replaced every 3 days until the predetermined dates. The 
collected culture media were used for cytotoxicity assay.
Sixteen days after culture, the culture media was 
removed and the cell monolayer was gently washed twice 
with ice-cold phosphate-buffered saline. The cell lysates 
were homogenized with ALP assay buffer (200 µL/well), 
followed by centrifugation (14,000× g for 5 minutes) to 
remove insoluble material. ALP activity in the cell lysate 
samples was measured at OD 405 nm (UVmax colorimeter, 
Molecular Devices, Sunnyvale, CA) with an ALP assay kit. 
ALP activity was expressed in nanomoles of p-nitrophenol 
produced per minute per microgram of protein. All experi-
ments were conducted in duplicate and repeated in three 
independent experiments.
effects of cD-eM complex  
on osteoclast formation
Osteoclasts were generated from a murine RAW 264.7 
macrophage cell line in the presence of RANKL.32 RAW 
264.7 cells were maintained in Dulbecco’s modified Eagle’s 
medium containing 10% fetal bovine serum and antibiotics 
(100 U/mL of penicillin G and 100 µg/mL of strepto-
mycin) at 37°C in a humidified incubator with 5% CO2. 
To   investigate the effects of erythromycin released from the 
CD-EM   conjugate on osteoclast formation, RAW cells were 
cultured in the presence of RANKL 50 ng/mL for up to 7 days 
in the presence of erythromycin 16 µg/mL, cyclodextrin 
37 µg/mL, and CD-EM 53 µg/mL. Culture media and drugs 
were replaced every 3 days. The collected cultured media at 
each time point were used for cytotoxicity assay.
TRAP staining was performed using a commercial kit as 
described elsewhere.14 In brief, RAW cells were fixed in 4% 
paraformaldehyde, followed by incubation at 37°C for 1 hour 
in a solution of naphthol AS-BI phosphoric acid, fast garnet 
GBC, and sodium tartrate. Following a rinse in deionized 
water, images of the stained cells were captured at 10× by 
a microscope (Carl Zeiss MicroImaging, Thornwood, NY). 
The mean percentage of TRAP+ cells was calculated by 
reading the stained plate at 525 nm in the ultraviolet-visible 
spectrophotometer through the built-in protocol.
cytotoxicity assay
Cell toxicity was determined by measuring the release of 
lactate dehydrogenase from dead or dying cells into the 
culture medium using a colorimetric method following the 
  manufacturer’s instructions. Blank culture medium was used 
as a control. Lactate dehydrogenase (LDH) activity was 
expressed as absorbance (OD) per mg protein. In addition, the 
potential cellular toxicity in cells treated with higher doses of 
erythromycin (1.6 mg/mL), cyclodextrin (3.7 mg/mL), and 
CD-EM (5.3 mg/mL) were evaluated using the Live⁄Dead® 
viability⁄cytotoxicity staining kit (Invitrogen, Camarillo, CA).
Statistical analysis
The statistical analysis was performed using the analysis of 
variance test, with the Schafer formula for post hoc multiple 
comparisons using the SPSS software package version 7.5 
(SPSS Inc, Chicago, IL). All treatments were performed in 
triplicate. Data were expressed as the mean ± standard error 
of the mean. A P value ,0.05 was considered to be statisti-
cally significant.
Results and discussion
1h-NMr
The  1H-NMR spectrum results demonstrated the presence 
of erythromycin in the CD-EM composite (Figure 1). Seven 
glucose units with identical conformations and hexagonal 
symmetry can be identified in Figure 1A by locating the 
integral peaks of 1–6 protons.33 The 1H-NMR spectrum of 
erythromycin in Figure 1B can be identified, consistent with 
earlier observations.34 The CD-EM complex prepared by both International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 1 500 mhz 1h-NMr spectra at 25°c of (A) cyclodextrin 14 mg (B) erythromycin 6 mg (C) cyclodextrin-erythromycin 20 mg (MV) (7/3, w/w) complex, (D) 20 mg 
of cyclodextrin-erythromycin (MVI) (7/3, w/w) complex in 750 µL of D2O ranging from 0.5 to 5.5 ppm. Important proton chemical shifts and peak integrations of solutes 
are labeled.
Abbreviations: MV, method V; MVI, method VI.
the MV and MVI methods has the same spectral   pattern, as 
shown in Figure 1C and D. The 13C-NMR   spectrum results also 
  demonstrate the presence of erythromycin in the CD-EM com-
plex (Figure 2). 13C signals for cyclodextrin at δ = 101.884, 
81.202, 73.150, 72.143, 71.906, and 60.394 ppm were the 
localization of C1, C2, C3, C4, C5, and C6, respectively, in 
D2O. The CD-EM spectra (MV and MVI) showed a similar 
pattern, with a minor   chemical shift (0.008 ppm) to a lower 
field only from C1 and C6 and carbon peaks at δ = 57 and 16 
ppm from erythromycin molecules.
The interaction between cyclodextrin and guest molecule 
occurs when guest molecule approaches the nonpolar cavity of 
cyclodextrin, which causes an upfield chemical shift (−δ) of 
guest molecule protons and a downfield chemical shift (δ) of 
host molecule carbons.35 Steric hindrance is known to be the 
decisive factor for preventing formation of a cyclodextrin-drug International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Table 1A Proton chemical shift of cyclodextrin
Proton H1 H2 H3 H4 H5 H6
Free-cD 4.953 3.543 3.852 3.471 3.744 3.764
cD-eM (MV) 4.951 3.540 3.847 3.467 3.736 3.761
cD-eM (MVI) 4.951 3.540 3.848 3.467 3.736 3.761
δ(MV) −0.002 −0.003 −0.005 −0.004 −0.008 −0.003
δ(MVI) −0.002 −0.003 −0.004 −0.004 −0.008 −0.003
Abbreviations:  cD,  cyclodextrin;  cD-eM,  cyclodextrin-erythromycin;  MV, 
method V; MVI, method VI.
7
3
.
1
5
0
7
2
.
1
4
3
6
0
.
3
9
4
7
1
.
9
0
6
8
1
.
2
0
2
1
0
1
.
8
8
4
1
0
1
.
8
9
2
1
0
1
.
8
9
2
7
3
.
1
5
0
7
2
.
1
4
3
6
0
.
3
8
7
7
1
.
9
0
6
7
3
.
1
5
0
7
2
.
1
4
3
7
1
.
9
0
6
5
7
.
5
2
0
6
0
.
3
8
7
5
7
.
4
6
8
1
6
.
9
0
4
1
6
.
8
3
0
8
1
.
2
0
2
8
1
.
2
0
2
1
2
3
4
5
6
CD
100 90 80 70 60 PPM
100 40 80 20 60 PPM
PPM
CD-EM(MVI)
CD-EM(MV)
100 80 60 40 20
6
1
3
4
5
2
6
1
3
4
5
2
C
H
1
C
H
C
H
C
H
C
H
C
H
C
H
C
H
C
H
C
H
C
H
C
H
C
H
C
H
C
H
H
O
H
O
H
O
1
6
5
4
3
2
O
O
O
Figure 2 500 mhz  13c-NMr spectra at 37°c of 30 mg of cyclodextrin, 30 mg of 
cyclodextrin-erythromycin  (MV)  (7/3,  w/w)  complex,  30  mg  of  cyclodextrin-
erythromycin (MVI) (7/3, w/w) complex in 1 mL of D2O. Important carbons (c1–c6 
and c from erythromycin) chemical shifts and peak integrations of solutes are labeled.
Abbreviations:  CD,  cyclodextrin;  cD-eM,  cyclodextrin-erythromycin;  MV, 
method V; MVI, method VI.
complex as a host-guest model.36 The large macrocyclic 
lactone ring structure in erythromycin is geometrically 
incompatible with the cavity dimensions of β-cyclodextrin. 
However, a nonhost-guest formation between cyclodextrin and 
erythromycin could be driven thermodynamically.
A selection of chemical shift variations obtained for eryth-
romycin from its free form to a complex form with cyclodextrin 
is presented in Table 1. Chemical shift variations from protons 
of erythromycin in the presence of cyclodextrin indicate the 
formation of a complex, especially protons (7′, 8, and 21) at 
the edge of the erythromycin molecules with larger shifts, 
which are attributed to the anisotropic shielding effect of 
the cyclodextrin cavity. However, other unaffected protons 
(3′, 4, 6, 12, 10, and 19) of erythromycin indicate that the 
erythromycin molecule did not enter the cyclodextrin   cavity. 
Instead, the shifts of protons (7′ and 8) directed outwards on 
two sugar units (L-cladinose and D-desosamine) indicate 
interaction of these two sugar units with the cyclodextrin 
molecules, while the shift of proton (21) from the diagonal 
position on the macrocyclic ring indicates the approach of 
another cyclodextrin molecule. Moreover, the shifts of C1 
and C6, although minor, indicate a cyclodextrin molecule 
approaching erythromycin on the smaller side of the cavity. 
There is no evidence of inclusion of the macrolide in the 
cyclodextrin cavity because there is no chemical shift of C2, 
C3, C4, and C5 from the 13C-NMR spectra. The formation of 
an intermolecular hydrogen bond between cyclodextrin and 
the guest molecules would ordinarily cause larger chemical 
shift variations (δ . 0.05) of cyclodextrin protons, particularly 
the H3 and H5 directed inside the cyclodextrin cavity. However, 
the chemical shift for cyclodextrin after complex formation 
shows no significant variations (δ , 0.01), demonstrating the 
absence of hydrogen bond formation between cyclodextrin 
and   erythromycin. Several assumptions have been made 
to interpret the interaction force during CD-drug complex 
formation, including Van der Waals interactions,37 hydrogen 
bonding,38 and release of strain energy in the ring of the cyclo-
dextrin molecule.39 Some aromatic molecules have been found 
to be able to be included in the cyclodextrin cavity by forming 
a hydrogen bond with H3 and H5.35   However, the interactive 
force between nonaromatic molecules of supermolecular size 
and cyclodextrin when forming a nonhost-guest complex is 
still controversial. Intermolecular Van der Waals forces and 
hydrophobic interactions are hypothesized to be the dominant 
driving forces for the formation of a   cyclodextrin-drug 
  complex.40 On the basis of the chemical shift of both cyclodex-
trin and erythromycin, we predict that the two sugar units and 
the diagonal position of erythromycin interacted with three 
cyclodextrin molecules via Van der Waals forces to form a 
packed complex. The three-dimensional topologic structure 
of the CD-EM complex is shown in Figure 3.
X-ray diffraction
Formation of the complex was found to alter the original crystal 
lattice of cyclodextrin and subsequently the x-ray diffraction International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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pattern.41 The x-ray diffraction spectra of cyclodextrin, CD-EM 
(MV and MVI), and erythromycin are shown in Figure 4. The 
spectrum of cyclodextrin indicates high crystallinity in cyclo-
dextrin due to the characteristic sharp peaks at (041), (141), 
(180), (042), (162), (222), (223), and (044). The spectrum of 
erythromycin shows low crystallinity with numerous weaker 
intensity peaks and some amorphous curves, even though the 
(100), (021), (060), (070), and (121) planes were identified 
to match with the standard spectrum of erythromycin. Both 
spectra of CD-EM (MV and MVI) showed a pattern similar to 
cyclodextrin, but with distinct peaks at (220), (250), (231), and 
(062), and a red color different from that in the cyclodextrin 
spectrum. Moreover, the original peaks at (042), (251), (223), 
and (044) with a blue color had disappeared and the double 
peaks at (130) merged into a single peak in the CD-EM com-
plex spectra. Some characteristic peaks of erythromycin [(060) 
and (121) with yellow color] were also seen in the CD-EM 
spectra. Generally, the spectra of CD-EM (MV) and CD-EM 
(MVI) were identical, with only some minor differences.
As new crystalline peaks were shown in spectra of CD-EM, 
phase transition for CD-EM complex during  preparation pro-
cess could be predicted. The conversion of a crystalline type 
for cyclodextrin and erythromycin revealed the formation of 
new complex. The intermolecular interaction of erythromycin 
and cyclodextrin could interrupt the original organization of 
cyclodextrin molecules and reformed crystalline lattices.
Ultraviolet-visible spectrometry
Formation of the cyclodextrin complex was also found to alter 
the original ultraviolet absorption spectrum.25 The ultraviolet 
Table 1B Proton chemical shift of erythromycin
Proton 3′ 4 6 7′ 8 10 12 19 21
Free eM 0.722 2.016 1.486 1.814 2.296 3.191 3.104 2.967 1.122
MV 0.734 2.014 1.488 1.785 2.243 3.204 3.110 2.961 1.060
MVI 0.736 2.014 1.492 1.783 2.235 3.204 3.112 2.968 1.060
δ(MV) +0.012 −0.002 +0.002 -0.029 -0.053 +0.013 +0.006 −0.005 -0.062
δ(MVI) +0.014 −0.002 +0.006 -0.031 -0.061 +0.013 +0.008 +0.001 -0.062
Note: Chemical shift variations with significance were specified in bold type.
Abbreviations: eM, erythromycin; MV, method V; MVI, method VI.
Table 1C carbon chemical shift of cyclodextrin
Carbon C1 C2 C3 C4 C5 C6
Free-cD 101.884 81.202 73.150 72.143 71.906 60.394
cD-eM (MV) 101.892 81.202 73.150 72.143 71.906 60.387
cD-eM (MVI) 101.892 81.202 73.150 72.143 71.906 60.387
δ(MV) 0.008 0 0 0 0 0.007
δ(MVI) 0.008 0 0 0 0 0.007
Note: Chemical shift variations with significance were specified in bold type.
Abbreviations:  eM,  erythromycin;  cD,  cyclodextrin  ;  MV,  method  V;  MVI, 
method VI.
Figure  3  Three-dimensional  molecular  structure  of  cyclodextrin-erythromycin 
complex. Yellow, erythromycin; pink, cyclodextrin 1; green, cyclodextrin 2; blue, 
cyclodextrin 3.
absorption spectral change on forming the CD-EM complex 
can be observed in Figure 5. The absorption peak was detected 
at 205 nm for free erythromycin. Absorption at 230 nm is 
consistent with a literature report for macrocyclic lactone. For 
the CD-EM complex, the presence of these two absorption 
peaks indicates the erythromycin substrate. A slight shift of 
the absorption peak for CD-EM from 205 nm to 200 nm can 
be interpreted as the effect of partial shielding of the excitable 
electrons in the cavity of cyclodextrin, while the shift of absorp-
tion from 230 nm to 235 nm is a bathochromic shift that usually 
happens after formation of a cyclodextrin complex.25
SeM analysis
To elucidate the formation of a CD-EM complex, morpho-
logic observation was performed using high-resolution SEM. 
Figure 6 shows this for cyclodextrin (6A, D), erythromycin 
(6B, E), and CD-EM (6C, F). A monoclinic   morphology of a 
cyclodextrin precipitate was observed under SEM   (Figure 6A 
and D) and this was consistent with analytic results from x-ray 
diffraction and literature reports,42 while   erythromycin powder 
was shown to be a semicrystalline precipitate (Figure 6B 
and E). Both the kneading and stirring processes facilitated 
interaction of cyclodextrin and erythromycin, altering their 
original crystalline structures and amorphization during 
freeze-drying, as shown in Figure 6C and F. For CD-EM 
prepared by both the MV and MVI methods, an appropriate International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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water content initiated the CD-EM interaction as well as 
cyclodextrin matrix formation. The continuous phase of the 
cyclodextrin matrix stabilized the interactive erythromycin 
molecule, leading to aggregation of CD-EM precipitates.31
Drug stability assay
Decomposition of delivered drug, occurring within the initial 
period of implantation, is one of the main limitations of local 
drug delivery approaches, particularly for periprosthetic drug 
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delivery.43–45 The formation of a cyclodextrin-drug complex 
aims to extend the duration of drug activity in an aqueous 
environment. In this assay, the concentration of erythromycin 
was dynamically decreased at 37°C over 20 hours for both 
pure erythromycin and CD-EM, as shown in Figure 7. The 
dramatic decrease of measurable erythromycin from about 
90% to 50% took place after incubation for 6 hours.   However, 
the fitting curves indicated that the rate of decrease of CD-EM 
was slower than for pure erythromycin, especially after 6 hours 
of incubation. At each time point after 6 hours, the percentages 
of measurable erythromycin from CD-EM were all higher 
than from pure erythromycin, indicating better stability. The 
invalidation of erythromycin in aqueous solution was susceptible 
to decomposition of the large macrocyclic lactone ring structure 
during the hydrolytic process.46 Protection of the integrity of 
the molecular structure of erythromycin in aqueous solution 
would help to increase its lifespan. By either the kneading or 
stirring method, formation of a CD-EM complex could pro-
vide a shielding effect for the erythromycin molecule from the 
surrounding cyclodextrin molecules, as described earlier. The 
packed cyclodextrin molecules improved the solubility of eryth-
romycin in aqueous solution and stabilized its molecular struc-
ture by preventing attack from nucleophiles during hydrolysis. 
Nonetheless, the noncovalent interaction between cyclodextrin 
and erythromycin enables release of entrapped free erythromy-
cin when the surrounding cyclodextrin becomes unstable.
Bactericidal activity
Erythromycin, one of the macrolide antibiotics, has been used to 
treat infectious diseases for more than 50 years. The molecular 
mechanism of its bactericidal activity is believed to involve 
binding to the 50s subunit of the bacterial 70s rRNA complex to 
interfere with aminoacyl translocation. Erythromycin is suscep-
tible to loss of bactericidal activity in an acidic environment.46 
We aimed to extend the bactericidal activity of erythromycin by 
embedding the drug in cyclodextrin nanoparticles. As shown in 
Figure 8, the results of a semiquantitative bactericidal activity 
assay show that bacterial growth was inhibited by treatment with 
the CD-EM complex in a dose-dependent manner (0–212 µg/
mL). This suggests that incorporation of erythromycin 
into cyclodextrin did not affect the bactericidal activity of 
erythromycin. To determine whether the CD-EM complex has 
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Figure 6 Scanning electron microscopic morphologies of (A, 100×; D, 300×) cyclodextrin, (B, 300×; E, 1000×) erythromycin and (C, 300×; F, 1000×) cyclodextrin-
erythromycin (MVI).
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longer bactericidal activity than free erythromycin, we repeated 
our bactericidal activity measurements in the presence of either 
the CD-EM complex (212 µg/mL, including erythromycin 
64 µg/mL) or the same amount of free erythromycin for up 
to 170 hours (Figure 8B). We found that treatment with both 
erythromycin and CD-EM resulted in persistent bacterial growth 
inhibition for up to 170 hours. Based on an exponentially fitting 
curve analysis, the bactericidal activity of CD-EM was sus-
tained for longer than for free erythromycin at the same dose. 
These data indicate that erythromycin has longer durability and 
bactericidal activity in aqueous solution when interacted with 
cyclodextrin, as compared with free erythromycin molecules.
effect of cD-eM complex on osteoblastic 
viability and differentiation
To assess the efficacy of the CD-EM complex, it was impor-
tant to show that the complex was noncytotoxic and had no 
inhibitory effect on osteoblast differentiation. In addition, 
it was critical to define the safe and optimal dosage of 
  erythromycin. The free cyclodextrin concentration was based 
on the amount of cyclodextrin present in the CD-EM complex 
at the indicated erythromycin concentration. For example, 
the highest concentration of erythromycin (1.6 mg/mL) is 
equivalent to approximately 5.3 mg/mL of CD-EM complex. 
Therefore, 3.7 mg/mL of free cyclodextrin was used as the 
control. As shown in Figure 9A, free cyclodextrin, erythro-
mycin, and the CD-EM complex did not show appreciable 
cytotoxicity in MC3T3 cells at erythromycin concentrations 
up to 1.6 mg/mL for a treatment period of 16 days, based on 
the live/dead cell staining assay. Intracellular ALP activity 
was measured to determine the effect of the CD-EM com-
plex on osteoblast differentiation. As shown in Figure 9B, 
treatment with erythromycin 1.6 mg/mL, cyclodextrin 
3.7 mg/mL, and CD-EM 5.3 mg/mL all inhibited ALP 
  activity significantly after 16 days in culture. We noticed that 
cyclodextrin 3.7 mg/mL achieved stronger inhibition of ALP 
activity than did erythromycin, while cells treated with the 
CD-EM complex showed the lowest ALP activity, although 
the difference was not statistically significant. Inhibition of 
ALP activity was closely related to the dose chosen. Our 
data demonstrated that MC3T3 cells treated with a lower 
concentration of cyclodextrin (37 µg/mL), erythromycin 
(16 µg/mL), or CD-EM complex (53 µg/mL) showed a 
slight increase in ALP activity compared with untreated 
cells (Figure 9B). This finding that a lower dose of CD-EM 
complex (with erythromycin 16 µg/mL) slightly increased 
ALP activity is important, because it will help us to design 
a safe and optimal range of drug loading for a periprosthetic 
drug delivery device. Our previous studies have indicated 
that erythromycin released from a periprosthetic device has 
bactericidal activity at a concentration of 10 µg/mL or less.16 
We have also noticed that treatment with erythromycin at 
a low concentration (5 µg/mL or less) leads to significant 
anti-inflammatory activity and inhibitory effect on osteoclast 
formation.13
Considering these facts and the data presented here, 
a high concentration of CD-EM complex drug loading is 
unnecessary and should be avoided in future experiments. 
More efforts are required to optimize the drug loading dose 
and the dynamics of drug release.
effect of the cD-eM complex  
on osteoclastogenesis
Recent studies have shown that RANKL and macrophage 
colony-stimulating factor are sufficient to induce differentiation 
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of bone marrow osteoclast progenitors into mature 
osteoclasts in vitro in the absence of stromal cells.47,48 There 
is accumulating evidence to indicate that enhanced osteoclast 
formation and activity is a hallmark of aseptic loosening/
osteolysis.49–52 Our previous studies have indicated that 
erythromycin is a promising osteoclast inhibitor targeting 
the NF-kB signaling pathway.13 To determine whether 
the CD-EM complex retains inhibitory activity against 
osteoclast formation, we cultured RAW 264.7 osteoclast 
precursor cells in the continuous presence of RANKL 
with or without CD-EM complex for 7 days. As seen in 
Figure 10, TRAP+ cells were developed in the presence of 
RANKL. Multinucleated (more than three nuclei) TRAP+ 
cells were counted as osteoclasts (Figure 10B). Mononu-
clear TRAP+ cells were counted as preosteoclasts (Fig-
ure 10C).13 Treatment with both erythromycin 16 µg/mL 
and an equivalent CD-EM complex significantly decreased 
the number of TRAP+ cells   (Figure 10C and E). However, 
treatment with free cyclodextrin had no inhibitory effect on 
the formation of TRAP+ cells (Figure 10D). Quantitative 
analysis of the percentage of TRAP+ cells in each well is 
summarized in the histogram shown in Figure 10. Through 
quantification results, we noticed that free erythromycin 
showed a better (albeit not statistically significant) inhibitory 
effect on the formation of TRAP+ cells than did the CD-EM 
complex, which had a significant inhibitory effect on 
osteoclastogenesis.   However, inhibition of formation of giant 
multinuclear cells by erythromycin and CE-EM showed a 
negligible difference. The mechanism involved needs to be 
investigated further. Nevertheless, our data indicate that the 
inhibitory effects of erythromycin are well preserved in the 
CD-EM complex.
cytotoxicity of cD-eM complex  
in Mc3T3 and rAW 264.7 cells
Although cyclodextrins are pharmaceutical excipients 
approved by the US Food and Drug Administration and 
expected to be safe for use,53 it is important to show that the 
CD-EM complex is not cytotoxic. Measurement of lactate 
dehydrogenase activity in culture medium is an indicator of 
increased permeability of the plasma membrane as a result of 
cytotoxicity. As shown in Figure 11A, treatment with free CD 
3.7 mg/mL, erythromycin 1.6 mg/mL, or CD-EM 5.3 mg/mL 
did not show noticeable   cytotoxicity in MC3T3 cells for up 
to 16 days. In addition, no significant increase in lactate 
dehydrogenase activity was found in RAW 264.7 cells with 
the same treatment as described for the MC3T3 cells up to 
7 days (Figure 11B). The mechanism of the slight increase 
in lactate dehydrogenase activity observed in all RANKL-
treated cells at day 4 is not clear. After 7 days in culture, 
we could not find any difference in lactate dehydrogenase 
activity between cells treated and not treated with CD-EM, 
indicating that the CD-EM complex is not cytotoxic to this 
cell line, even at a very high concentration.
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Conclusion
Our study results indicate that the hydrophobic erythromycin 
molecule can interact with β-cyclodextrin via either the 
kneading or cogrinding method to form a nonhost-guest 
CD-EM complex. We found that the intermolecular 
packing structure of the CD-EM complex enabled extended 
stability in aqueous solution, durable bactericidal activity, 
an inhibitory effect on osteoclastogenesis with little effect 
on osteoblastic viability and differentiation, and safety with 
no cytotoxicity. These attributes are especially important in 
delivering a sufficient amount of erythromycin to the site of 
periprosthetic inflammation and reducing local inflammation 
in a sustained manner.
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